Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Anderson

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Clinical and Diagnostic Laboratory Immunology|July 1, 1995
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionR Q Warren, M T Wong, G P Melcher, et al.
Cancer Research|December 1, 1984
American cancer society Phase I trial of naturally produced beta-interferonM J Hawkins, S E Krown, E C Borden, et al.
Experimental Hematology|December 1, 1985
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejectionM J Bozdech, P M Sondel, M E Trigg, et al.
Journal of Clinical Microbiology|February 1, 1995
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolatesR Q Warren, M T Wong, G P Melcher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Clotting Factor (Cf) Product Use And Same-Day Risk For Thrombotic Adverse Events (Tes), As Recorded In Large Health Care Database During 2008-2013 Study PeriodB F Ekezue, G Sridhar, H S Izurieta, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
The Journal of Infectious Diseases|March 10, 2001
Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjectsL A Pinto, V Blazevic, S A Anderson, et al.
Journal of Clinical Microbiology|January 1, 1992
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United StatesR Q Warren, W M Nkya, J F Shao, et al.
Vox Sanguinis|December 4, 2014
Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012M Menis, R A Forshee, S A Anderson, et al.
Vox Sanguinis|July 16, 2013
Transfusion-associated circulatory overload (TACO) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011M Menis, S A Anderson, R A Forshee, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Clinical and Diagnostic Laboratory Immunology|July 1, 1995
Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progressionR Q Warren, M T Wong, G P Melcher, et al.
Cancer Research|December 1, 1984
American cancer society Phase I trial of naturally produced beta-interferonM J Hawkins, S E Krown, E C Borden, et al.
Experimental Hematology|December 1, 1985
Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejectionM J Bozdech, P M Sondel, M E Trigg, et al.
Journal of Clinical Microbiology|February 1, 1995
Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolatesR Q Warren, M T Wong, G P Melcher, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Clotting Factor (Cf) Product Use And Same-Day Risk For Thrombotic Adverse Events (Tes), As Recorded In Large Health Care Database During 2008-2013 Study PeriodB F Ekezue, G Sridhar, H S Izurieta, et al.
The Journal of Infectious Diseases|December 1, 1993
Longitudinal analysis of the humoral immune response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjectsM T Wong, R Q Warren, S A Anderson, et al.
The Journal of Infectious Diseases|March 10, 2001
Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjectsL A Pinto, V Blazevic, S A Anderson, et al.
Journal of Clinical Microbiology|January 1, 1992
Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United StatesR Q Warren, W M Nkya, J F Shao, et al.
Vox Sanguinis|December 4, 2014
Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012M Menis, R A Forshee, S A Anderson, et al.
Vox Sanguinis|July 16, 2013
Transfusion-associated circulatory overload (TACO) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011M Menis, S A Anderson, R A Forshee, et al.
Pageof 12